Nature Communications (May 2018)
MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity
- Anna Skucha,
- Jessica Ebner,
- Johannes Schmöllerl,
- Mareike Roth,
- Thomas Eder,
- Adrián César-Razquin,
- Alexey Stukalov,
- Sarah Vittori,
- Matthias Muhar,
- Bin Lu,
- Martin Aichinger,
- Julian Jude,
- André C. Müller,
- Balázs Győrffy,
- Christopher R. Vakoc,
- Peter Valent,
- Keiryn L. Bennett,
- Johannes Zuber,
- Giulio Superti-Furga,
- Florian Grebien
Affiliations
- Anna Skucha
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Jessica Ebner
- Ludwig Boltzmann Institute for Cancer Research
- Johannes Schmöllerl
- Ludwig Boltzmann Institute for Cancer Research
- Mareike Roth
- Research Institute of Molecular Pathology
- Thomas Eder
- Ludwig Boltzmann Institute for Cancer Research
- Adrián César-Razquin
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Alexey Stukalov
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Sarah Vittori
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Matthias Muhar
- Research Institute of Molecular Pathology
- Bin Lu
- Cold Spring Harbor Larboratory
- Martin Aichinger
- Research Institute of Molecular Pathology
- Julian Jude
- Research Institute of Molecular Pathology
- André C. Müller
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Balázs Győrffy
- MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Second Department of Pediatrics, Semmelweis University
- Christopher R. Vakoc
- Cold Spring Harbor Larboratory
- Peter Valent
- Department of Internal Medicine I. Division of Hematology and Hemostaseology, Ludwig Boltzmann Cluster Oncology, Medical University of Vienna
- Keiryn L. Bennett
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Johannes Zuber
- Research Institute of Molecular Pathology
- Giulio Superti-Furga
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Florian Grebien
- Ludwig Boltzmann Institute for Cancer Research
- DOI
- https://doi.org/10.1038/s41467-018-04329-y
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
In leukemia, diverse fusion proteins involving the MLL gene can drive oncogenic activity. Here, the authors describe a dependency of MLL-leukemia cells on the methyltransferase SETD2 to maintain genomic integrity during leukemia initiation and maintenance.
